Assessment of Supportive Care and Educational Needs to Guide Quality Care Improvements for Patients With Locally Advanced and Metastatic Bladder Cancer
NCT06412874 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93
Last updated 2026-04-27
Summary
The overall goal of this study is to facilitate care improvements for bladder cancer patients with locally advanced or metastatic disease by designing and evaluating a patient need assessment screening tool to be used, in the future, as standard screening measure. Adult individuals diagnosed with Stage 4 incurable locally advanced or metastatic bladder cancer will be included in this study and asked to participate in a focus group, complete a screening tool, or complete a survey. All data collected will be linked to a study ID number and HIPAA identifiers will not be linked to study data. Identifying information (ie: name, mrn, email, phone number) will be utilized for study recruitment and identifying eligible patients. Any disclosure of the human subjects' responses outside the research would not reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects' financial standing, employability, educational advancement, or reputation.
Conditions
- Screening Tool
- Focus Group
Interventions
- OTHER
-
Screening tool
Participants will complete a screening tool survey
Sponsors & Collaborators
- collaborator INDUSTRY
-
Icahn School of Medicine at Mount Sinai
lead OTHER
Principal Investigators
-
Nihal Mohamed, PhD · Icahn School of Medicine
Eligibility
- Min Age
- 18 Years
- Max Age
- 89 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-05-20
- Primary Completion
- 2025-08-09
- Completion
- 2025-08-09
Countries
- United States
Study Locations
More Related Trials
-
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
NCT01050504 ·Status: RECRUITING
-
Health-Related Quality of Life in Patients With Bladder Cancer
NCT00744744 ·Status: COMPLETED
-
Drug Screening Using IMD in Bladder Cancer
NCT06204614 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1
-
Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma
NCT00461851 ·Status: COMPLETED ·Phase: PHASE2
-
Bladder Cancer Patient-Reported Outcomes
NCT01090388 ·Status: COMPLETED
-
Recovery Support for Bladder Cancer Patients and Caregivers
NCT04055311 ·Status: COMPLETED ·Phase: NA
-
A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
NCT07122414 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
NCT02500121 ·Status: COMPLETED ·Phase: PHASE2
-
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
NCT05136898 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
NCT04172675 ·Status: COMPLETED ·Phase: PHASE2
-
Quality of Life and Symptom Management in Patients With Bladder Cancer
NCT00772018 ·Status: COMPLETED
-
Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer
NCT01442519 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma
NCT04486781 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
NCT05327647 ·Status: RECRUITING ·Phase: PHASE2
-
Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers
NCT03413982 ·Status: RECRUITING
-
Prognostic Biomarkers in Patients With Urothelial Carcinoma
NCT04872036 ·Status: COMPLETED
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
NCT07048496 ·Status: RECRUITING ·Phase: NA
-
First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma
NCT03324282 ·Status: TERMINATED ·Phase: PHASE2
-
Personalized Urine Biomarker for Patients With Bladder Cancer
NCT05467267 ·Status: UNKNOWN
-
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03547973 ·Status: RECRUITING ·Phase: PHASE2
-
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
NCT00234039 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC
NCT06186414 ·Status: RECRUITING ·Phase: PHASE1
-
Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases
NCT06870253 ·Status: ACTIVE_NOT_RECRUITING
-
Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health
NCT00776178 ·Status: COMPLETED
-
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
NCT04586244 ·Status: TERMINATED ·Phase: PHASE2